Pfizer tests drug interaction in tiny early study
NCT ID NCT07575945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study looks at whether the antifungal itraconazole changes how the body handles a new drug called PF-08642534. Fourteen healthy adults will take the study drug with and without itraconazole. The goal is to see how the drug levels change, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PF-08642534 and itraconazole
- What this could lead to
- If successful, this study will show whether itraconazole changes how PF-08642534 is processed, helping guide future dosing recommendations.
- What could go wrong
- This is a very early Phase 1 study in only 14 healthy people, so results may not predict effects in patients or reflect real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New Haven Clinical Research Unit
New Haven, Connecticut, 06511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does drug particle size matter? a study puts prifetrastat to the test
- Smoking may weaken dental fillings, new study suggests
- Pfizer tests heart drug safety in healthy volunteers
- Can a drug and probiotic combo turn back the clock on aging?
- Pfizer checks if new atirmociclib tablet matches the old one
- Ibuzatrelvir drug study in healthy chinese volunteers completed